Breadcrumb navigation

NEC's AI Drug Development Business

We utilize a broad range of IT and AI technologies in various drug development activities.

NEC develops cancer vaccines using AI technologies.


This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.

Partner & Pipeline

Target Indication: Liver cancer, Gastrointestinal cancer
A spin-off company of NEC that was established in 2016. Its peptide vaccine drug was identified by NEC's AI and clinical trials have been initiated.
Target Indication: Ovarian cancer, Head and neck cancer
Transgene and NEC to start clinical development of lead myvac™ individualized immunotherapy, TG4050, in 2019. This collaboration harnesses Transgene’s myvac™ platform and NEC’s long-standing Artificial Intelligence capabilities to develop an individualised neoantigen cancer vaccine.
NEC has made a Series A strategic investment in BostonGene, a pioneer in the use of biomedical software for advanced patient analysis. BostonGene has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno and targeted therapies.
Parker Institute for Cancer Immunotherapy
NEC becomes the first Japanese company to join the Parker Institute for Cancer Immunotherapy’s international TESLA consortium. This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the most effective ways to use algorithms for predicting which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.
Target Indication: Various solid tumors
Vaximm and NEC to initiate clinical development of a personalized neoantigen cancer vaccine using NEC’s Neoantigen Prediction System and VAXIMM’s proprietary T-cell immunotherapy technology. The vaccine is planned to be evaluated in a Phase I clinical trial in 2020.

Press release